to face and intertriginous areas 6 . Inclinical trials, the common adverse effects were burning, pruritus, and erythema of skin. Burning sensation at the site of application is by far the most frequently reported adverse effect and is found in roughly 37 to 46% of adults and children treated with 0.03% tacrolimus,and 26 to 58% of those treated with 0.1% tacrolimus ointment 7 . Particular attention has been paid to skin infections as a potential complication of topical treatment with an immunosuppressive agent. Viral, fungal, and bacterial infections have all been reported 8 . Apart from mild to moderate burning, erythema, and pruritus, the use of tacrolimus ointment can cause folliculities,acne, Kaposi's varicelliform eruptions, eczema herpeticum and herpes simplex infections. Increased skin sensitivity to hot and cold and alcohol intolerance have also been reported 9 . Occurrence of recurrent skin tags, rosacea like granulomatous eruptions, rosaceiform dermatitis, mucosal hyperpigmentation, tinea incognito, molluscumcontagiosumand verruca vulgarishave recently been reported. The cutaneous viral infection in particular is alarming and may be caused by local immunosuppressions 10 . Although there is a theoretic concern that topical immunomodulatory therapy with tacrolimus and pimecrolimus may increase the risk of cancer, there is no evidence to date to suggest an increased risk of cutaneous or visceral cancer. The European Agency for the Evaluation of Medicinal Products has not recommended any change in labeling or approval of these topical agents. There may still be clinical situations where such off-label treatment is seen as a lesser risk than available alternatives such as oral administration of an immunosuppressant, and limited data on safety are emerging 11 . There are numerous treatment options available for vitiligo but none is universally safe. Very recently topical tacrolimus 0.1% is being produced and marketed in our country but its safety has not been studied in our population yet. This study is designed to observe the safety of using topical tacrolimus 0.1% in patients of vitiligo.
Materials and Methods
A clinical trial was conducted in the department of Dermatology and Venereology, BMC, Dhaka. Study period of the trial was January 2010 to July 2010 and patients with vitiligo (focal and segmental) were the study population. Finally thirty patients, who matched the inclusion criteria, were selected for the study. Sampling technique was purposive type. History and physical findings were recorded in a structured questionnaire. Ethical approval was taken from ethical Committee of BMC, Dhaka.
Inclusion criteria: * Vitiligo patients of both sex and above 2 years of age. * Patient who had not received any treatment for vitiligo (both systemic and topical) in the previous 2 months prior to inclusion. * Vitiligoof focal and segmental.
Exclusion criteria: * Pregnant women and lactating mother. * Known case of tacrolimus hypersensitivity. * Vitiligouniversalis with widespread involvement.
Procedure of data collection:
A total number of thirty subjects of vitiligo were primarily selected from thedepartment of Dermatology and Venereology, BMC, Dhaka and complete history, general physical and dermatological examinations was done for all enrolled subjects. For women of reproductive age reproductive history, menstrual history, lactation and pregnancy plan was carefully judged. Before inclusion in the study, all the participants and parents of children wereelaborately informed about the natural history and the prognosis of the disease, proper application procedures for the therapy, possible therapeutic outcomes and adverse effects associated with therapy, so that they can make independent decision about their participation. They were assured of strict privacy and secrecy of information on all occasions as such necessary measures were taken before hand. Photographs of all lesions and clinical assessment at baseline and follow-up visit after three months were taken for subsequent assessment and further comparison. Each individual lesion was treated with tacrolimus 0.1% ointment twice daily for three months. Generally, the repigmentation was recorded every 4 weekly for three months and outcome measures graded as none (no repigmentation), mild (less than 50% repigmentation), moderate (50-75% regimentation), and complete (more than 75% repigmentation). Observation and results of the clinical study and statistical analysis were presented by suitable chart, tables, graphics and diagram.
Result
This study was carried out on thirty vitiligo (focal and segmental) patients for a period of 12 weeks at the department of Dermatology and Venereology, BMC, Dhaka. Majority of patients suffering from vitiligo 20(66.6%) were under the age of 40 years. The highest percentage 13(43.3%) was in the age of 11-20 years. Sex ratio revealed higher in case of female 18(60%), with a male-female ratio 1:1.5(table-I). Table II showed 5(16.67%) patients had vitiligo among their families. Repigmentation was observed in 8(26.7%) subjects at the end of 4 th week, 15 (50.1%) subjects at 8 th week and 25(83.3%) subjects after 12 weeks of therapy. It was seen from figure I that 25(83%) subjects had no adverse effect and 5(17%) subjects were suffered from different adverse effects of the drug. Pruritus observed 2(6.7%)subjects and burning in3(10%) subjects. 
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Discussion
In this study, 43.3% subjects were within the age group of 11-20 years and 20% were in the age group of 21-30 years which mostly correlates with the findings of many other study, like the percentage of subjects in the age group of 11-20 years was 46% in one study12 and 29.7% in another study 13. Sex ratio revealed higher in case of female (60%), with a male-female ratio 1:1.5. According to different previous studies adults and children of both sexes are equally affected although the greater number of reports among females is probably due to the greater social consequences to women and girls affected by this condition14, 15, 16. Family history has variously been reported with a range between 6.25% to 38%17. However, in our study family history was 5(16.67 %)which corroborates with another study (12%)18. Though it is very difficult to judge the efficacy of treatment without studying the compliance rate and follow-up for a long time; in this study overall response to topical tacrolimus in the treatment of vitiligo has been observed, which shows 25 (83.3%) subjects had at least some repigmentation at the end of study, which concurs with other similar studies; as for example 83.3%11,100%19, 86.4%20and 84%21.Xu AE et al. treated focal, segmental and generalized vitiligo with 0.1% topical tacrolimus for four months11,but we treated focal and segmental vitiligo for three months with same repigmentation score, so it was faster in our study. Skin typing of Bangladeshi subjects and UVB exposure may stimulate the efficacy of topical tacrolimus, because most of the population of our country is worked in sun light.In this study only two subjects reported pruritus (6.7%), and three mild irritation and burning (10%). These are the clinical adverse effects of topical tacrolimus described in the literature which includes pruritus, irritation, burning and erythema of skin. No serious adverse events occurred during the 12 week study. The symptoms are mild intensity that concurs with the references; as we find burning sensation found in 13.3%11, 3.5%21 of cases and pruritus and burning in 12% 20 of cases. Nobody discontinued the therapy for serious adverse effects. In this study dermatological adverse effects were infrequent and mild, so all the patients completed the therapy. This study found that topicaltacrolimus 0.1% ointment to be safe in the treatment of vitiligo, with reduction in the number of vitiligenous spots by increased repigmentation significantly.
Conclusion:
This study reflects that topicaltacrolimus ointment 0.1% is a safe topical therapeutic option for the treatmentvitiligo. Proper selection of patient as well as appropriate topical use of drug for adequate duration responds well to reduce the number and size of vitiligenous spots with minimum adverse effects.
Safety of 0.1% topical tacrolimus
